|
⚲
|
| Keyboard |
| Parkman Healthcare Partners LLC
✚
|
|
|---|---|
| CRD # | 300701 |
| SEC # | 801-114849 |
| CIK # | 0001777015 |
| AUM | 1,744.0 M (2026-03-27) |
| Employees | 12 (67% Investors, 0% Brokers) |
| Fees | |
| Minimum | |
| Phone | 203-516-3690 |
| Address | 700 Canal Street Stamford, CT 06902 |
| Source | [IAPD] [EDGAR] [Website] [LinkedIn] |
| Total AUM ($M) |
|---|
| Fees and Compensation — Form ADV Part 2A (3/27/2026) [Brochure] |
|---|
Item 5 – Fees and Compensation (Continued)
Account, the Adviser is compensated either through a pre-negotiated monthly fee or on a
quarterly basis in arrears. Additionally, the Managed Accounts pay the Adviser an annual
performance fee, equal to a set percentage of net appreciation of the assets held by such
accounts. Such fees are generally paid by the owners of the applicable accounts and not
deducted from the assets of the Managed Account.
B. Fees are generally deducted by the Adviser from the Fund. Fees are not automatically
deducted from the Managed Accounts and are billed based on the terms of the relevant
investment advisory agreement that was negotiated with the applicable Managed Account.
C. Any other types of fees or expenses Clients may pay in connection with Parkman’s advisory
services will depend on the respective Client’s advisory agreement. The Clients may incur
brokerage and other transaction costs. The Client will generally bear all expenses relating to
its ongoing structure and operation (including direct expenses of the Client) pursuant to the
terms of its Offering Documents. Clients may incur expenses relating to the organization,
maintenance, and operation of the Client accounts including, but not limited to, registered
agent fees, costs related to compliance, regulatory and AML matters, costs associated with
gaining access to non-U.S. markets, all direct trading expenses, including but not limited to,
execution and clearing commissions, transaction charges, ticket charges, fees and expenses
incurred in the borrowing and lending of securities, custodian and trustee fees, bank service
fees, transfer taxes, withholding taxes, administrative fees (including fees paid to the Client’s
administrator) accounting, tax preparation and audit fees, fees paid to third-parties retained
by the Client related to the delivery of the trade file, and other fees and expenses related to
the purchase, sale or other disposition of assets. Please see the disclosures in Item 12 as it
relates to Parkman’s brokerage activities.
D. As stated above, the Management Fees are deducted directly from the Fund and paid quarterly
in advance. The Management Fee is prorated for any period that is less than one full quarter
for investments made by new or existing investors and refunded on a prorated basis upon
withdrawal or redemption from the Fund prior to quarter-end.
As described in detail in the relevant investment advisory agreements for each Managed
Account, the Managed Accounts pay Parkman management fees either monthly or quarterly
in arrears based on the Account’s percentage of the Adviser’s assets under management. In
the event of the termination of a Managed Account’s agreement, the Managed Account shall
pay prorated management fee through the end of the foregoing notice period.
E. Other than as described above, neither Parkman nor any of its supervised persons receive any
additional compensation from the sale of securities or other investment products. |
| Account Minimums and Types of Clients — Form ADV Part 2A (3/27/2026) [Brochure] |
|---|
Item 7 - Types of Clients As mentioned in Item 4, Parkman provides investment advisory services to its Clients based on the investment objectives and strategies described in the Offering Documents. Admission as an Investor in the Fund is not open to the general public. The Fund is not intended as a complete investment program and is designed only for persons who are able to bear the economic risk of the loss of their entire investment in the Fund and who have a limited need for liquidity in their investments. Fund interests will generally be sold only to qualified investors who are “accredited investors” under Regulation D of the Securities Act of 1933, as amended, and “qualified purchasers” as such term is defined in Section 2(a)(51) of the Investment Company Act. The minimum initial investment in the Fund is $1,000,000, subject to reduction in the sole discretion of the General Partner. In general, the Fund will accept investments monthly. Investments will be made in cash or, in the General Partner’s sole discretion, in securities or partly in cash and partly in securities. The General Partner may admit additional or substitute general partners (i) as of the beginning of any calendar quarter upon 60 calendar days’ prior written notice to all Investors, (ii) at any time with the consent of the majority in interest of the Investors, or (iii) at any time if such additional or substitute general partners are affiliates of the General Partner or its principals or an estate planning vehicle established for the benefit of a family member. |
| Sector | Form 13F Holdings | Value ($M) | |
|---|---|---|---|
| Stryker Corp | 50.9 | ||
| Dexcom Inc | 43.3 | ||
| Insulet Corp | 32.9 | ||
| Lilly Eli & Co | 31.8 | ||
| PTC Therapeutics Inc | 29.4 | ||
| Xenon Pharmaceuticals Inc | 28.9 | ||
| Boston Scientific Corp | 28.2 | ||
| CVS Caremark Corp | 27.8 | ||
| Arcus Biosciences Inc | 26.1 | ||
| Livanova PLC | 25.7 | ||
| View All | |||
| Holdings by Sector ($M) |
|---|
| Type | Form D Funds | Date | Sold | AUM |
|---|---|---|---|---|
| PE | Parkman Venture Partners SPV I LP | [2023-03-27] | 9.2 M | 4.1 M |
| Offered $9,250,000 · Filed 2022-05-23 (D) · Exemption 506(b), 3(c), 3(c)(7) · Duration One year or less · Revenue Decline to Disclose | ||||
| HF | Parkman HP Master Fund LP | [2019-07-02] | 64.5 M | 718.9 M |
| Filed 2025-05-30 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose | ||||
| AUM Breakdown | Accounts | AUM ($M) |
|---|---|---|
| By Client Type | ||
| (a) Individuals (other than high net worth individuals) | 0 | 0.0 |
| (b) Individuals (high net worth individuals) | 0 | 0.0 |
| (c) Banking or thrift institutions | 0 | 0.0 |
| (d) Investment companies | 0 | 0.0 |
| (e) Business development companies | 0 | 0.0 |
| (f) Pooled investment vehicles | 7 | 1,744.0 |
| (g) Pension and profit sharing plans | 0 | 0.0 |
| (h) Charitable organizations | 0 | 0.0 |
| (i) State or municipal government entities | 0 | 0.0 |
| (j) Other investment advisers | 0 | 0.0 |
| (k) Insurance companies | 0 | 0.0 |
| (l) Sovereign wealth funds and foreign official institutions | 0 | 0.0 |
| (m) Corporations or other businesses not listed above | 0 | 0.0 |
| (n) Other | 0 | 0.0 |
| Total | 7 | 1,744.0 |
| By Discretionary | ||
| Discretionary | 7 | 1,744.0 |
| Non-Discretionary | 0 | 0.0 |
| Total | 7 | 1,744.0 |
| By Non-United States Persons | ||
| Non-United States Persons | 1,744.0 | |
| United States Persons | 0.0 | |
| Total | 7 | 1,744.0 |
| Form D Directors | Role | # Filings | # Firms | 2011 - 2026 |
|---|---|---|---|---|
| Parkman Healthcare Partners LLC | Executive Officer | 3 | 2 | |
| Parkman Venture Partners GP LLC | Executive Officer | 1 | 1 | |
| Parkman HP Fund GP LLC | Executive Officer | 1 | 1 |
| EDGAR Form | CIK | 2011 - 2026 |
|---|---|---|
| 13F-HR | [0001777015] | |
| 3 | [0001777015] | |
| 4 | [0001777015] | |
| SC 13G | [0001777015] |
| Form 13D/13G Filer | Form 13D/13G Subject | Filed |
|---|---|---|
| Parkman Healthcare Partners LLC | InspireMD Inc | [2025-11-14] |
| Parkman Healthcare Partners LLC | Plus Therapeutics Inc | [2022-02-04] |
| Firm Profile (Form ADV) | |
|---|---|
| Serves | Institutional |
| Fund Types | Hedge Fund, Private Equity |
| LEI | 549300SDS6C71DAN3T72 |
| Form 3/4/5 Subject | 2011 - 2026 |
|---|---|
| Martinez Gregory | |
| Parkman Healthcare Partners LLC | |
| Spruce Biosciences Inc |
| Insider Transaction (Form 3/4/5) | Date | Action | Shares | Price | Value ($) |
|---|---|---|---|---|---|
|
Spruce Biosciences Inc SPRB
Common Stock, $0.001 par value per share
|
2025-10-06 | Sell | 232 | $19.33 | 4,485 |
|
Spruce Biosciences Inc SPRB
Common Stock, $0.001 par value per share
|
2025-10-06 | Sell | 25 | $17.46 | 436 |
|
Spruce Biosciences Inc SPRB
Common Stock, $0.001 par value per share
|
2025-10-06 | Buy | 256 | $17.91 | 4,585 |
|
Spruce Biosciences Inc SPRB
Common Stock, $0.001 par value per share
|
2025-10-06 | Sell | 232 | $19.33 | 4,485 |
|
Spruce Biosciences Inc SPRB
Common Stock, $0.001 par value per share
|
2025-10-06 | Buy | 256 | $17.91 | 4,585 |
|
Spruce Biosciences Inc SPRB
Common Stock, $0.001 par value per share
|
2025-10-06 | Sell | 25 | $17.46 | 436 |
| Comparable Firms | State | AUM |
|---|---|---|
|
Tensile Capital Management LP
✚
|
CA | 1,796.0 M |
|
Morgan Creek Capital Management LLC
✚
|
NC | 1,790.2 M |
|
QVT Financial LP
✚
|
NY | 1,786.7 M |
|
Alta Park Capital LP
✚
|
CA | 1,779.6 M |
|
Great Point Partners LLC
✚
|
CT | 1,777.1 M |
|
OFS Capital Management LLC
✚
|
IL | 1,760.0 M |
|
RCF Management LLC
✚
|
CO | 1,757.0 M |
|
Long Path Partners LP
✚
|
CT | 1,732.8 M |
|
Galaxy Digital Capital Management LP
✚
|
NY | 1,723.0 M |
|
Wexford Capital LP
✚
|
FL | 1,720.5 M |